Weekly News Amount
Total
${lastRankDetail.pages.length}
Financing ${lastRankDetail.financing_pages.length}
Product ${lastRankDetail.product_pages.length}
Negative ${lastRankDetail.sentiment_pages.length}
JSI is a small molecule anti-cancer new drug developer, dedicated to the research and development of small molecule tumor immune new drugs and targeted tumor new drugs. Its business involves drug molecule design, chemical synthesis, in vivo and in vitro biological activity evaluation, ADMET property test and other fields

Transactions

Funding 1 Fundings
Date Amount Round Relative News
Jun 2020 Nearly 100 million CNY Series A+ JSI Completed Nearly 100 Million Yuan A+ Round of Financing and Juming Venture Capital Led Investment

Signals

Events ${currentEventsPage.count} Events
Events (${currentEventsPage.count}) Date
Nothing Happens :-(
${e.desp} ${e.date}
News ${ rankDetail.pages.length } News Articles ${currentTimeRange.start} ~ ${currentTimeRange.end}
Article (${rankDetail.pages.length}) Tag
${article.en_title} ${article.tag}
Industry Financing Info

Research

Intelligence 0 Research Briefs

Competition

Competitors 0 Competitors